Cargando…
Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis
BACKGROUND: Millions of patients receive vitamin K antagonist (VKA) therapy worldwide. Annually 0.2–1 % of all VKA users develops an intracranial hemorrhage (ICH). Prothrombin complex concentrate (PCC) is administered to restore the INR ≤ 1.5 in an attempt to limit hematoma growth. In order to facil...
Autores principales: | Abdoellakhan, Rahat Amadkhan, Miah, Ishita Parveen, Khorsand, Nakisa, Meijer, Karina, Jellema, Korné |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226998/ https://www.ncbi.nlm.nih.gov/pubmed/27052728 http://dx.doi.org/10.1007/s12028-016-0248-8 |
Ejemplares similares
-
Randomised controlled trial protocol to evaluate a fixed dose prothrombin complex concentrate against the variable dose in vitamin K antagonist related bleeding (PROPER3)
por: Abdoellakhan, Rahat A, et al.
Publicado: (2018) -
Clinical outcome of patients with a vitamin K antagonist‐associated bleeding treated with prothrombin complex concentrate
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2017) -
Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding
por: Abdoellakhan, Rahat A., et al.
Publicado: (2019) -
A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding
por: Jaspers, Tessa, et al.
Publicado: (2021) -
Use of Prothrombin Complex Concentrate for Vitamin K Antagonist Reversal before Surgical Treatment of Intracranial Hemorrhage
por: Wong, Yun
Publicado: (2011)